3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

Pegcetacoplan (PEG) is a C3 complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PEG was superior to eculizumab (ECU; C5-inhibitor) in improving hemoglobin (Hb) levels and clinical outcomes at Week 16 (phase 3 PEGASUS trial NCT03500549). Here, we report efficacy and s...

Celý popis

Podrobná bibliografia

Vydané v:	Experimental hematology Ročník 100; s. S97
Hlavní autori:	de Latour, Régis Peffault, Szer, Jeffrey, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio, Hillmen, Peter
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Elsevier Inc 01.08.2021
Predmet:	Advanced Basic Science Hematology, Oncology, and Palliative Medicine
ISSN:	0301-472X, 1873-2399
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!